Ladenburg Thalmann

Ladenburg Thalmann has published a research report on GSV Capital (NASDAQ: GSVC) and has lowered the price target from $20.25 to $17.75 as the company has opportunities for exposure in private, emerging growth companies. In the report, Ladenburg Thalmann writes, "According to recent data from...

Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation. In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we...

According to a research report this morning, Ladenburg Thalmann reduces its PT on Bioanalytical Systems (NASDAQ: BASI) from $2.75 to $2.25 following disappointing Q2-2012. Ladenburg Thalmann stated, “The Company announced losing $1.86MM and $0.27 per share on revenue of $6.97MM as compared with...

According to a research report published this morning, Ladenburg Thalmann has increased Prospect Capital's (NASDAQ: PSEC) PT from $11 to $11.50. In the report, Ladenburg Thalmann commented, "During 3Q12 PSEC closed on $171 million of new and follow-on portfolio investments versus $155 million in...

According to a research report published this morning, Ladenburg Thalmann has lowered Full Circle Capital's (NASDAQ: FULL) PT from $8 to $7.50. Ladenburg Thalmann commented in the report, "FULL held its earnings call on May 11, 2012 and reported 3Q12 NOI per share of $0.18 which missed our $0.21...

Ladenburg Thalmann reduces its price target from $38 to $37 on Buy-rated Chesapeake Midstream Partners (NYSE: CHKM) as the firm misses consensus estimates on Earnings Per Unit in Q1. Ladenburg Thalmann notes, "1Q12 Earnings Per Unit (EPU) Below Consensus But In-Line With Our Expectations. For...

Listed below are Benzinga's Top Upgrades: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals (NASDAQ: KERX) to Buy: Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following yesterday's announcement of the perifosine data. Zerenex's Phase III program...

Listed below are today's Top Downgrades at Benzinga: ISI Group Downgrades Staples (NASDAQ: SPLS) to Sell: ISI Group commented, "We are downgrading Staples to Sell from Hold, as the stock has bounced 8% ytd, yet secular fundamentals have not improved, European headwinds remain, and our surveys...

According to a research report published this morning, Ladenburg Thalmann has upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, and established a $3 PT. In the report, Ladenburg Thalmann said, "The importance of the Zerenex program has substantially increased following...

According to a research report published this morning, Ladenburg Thalmann has downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Buy to Neutral and removed its $19 PT. Ladenburg Thalmann commented in the report, "Our prior AMAG rating had been partially justified by expectations for a potential...